670
Participants
Start Date
April 16, 2018
Primary Completion Date
April 16, 2033
Study Completion Date
April 16, 2033
Study of the occurrence of Carcinoid Heart Disease
"Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, …) biological parameters (urinary 5HIAA, NT-ProBNP …) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease."
CHU Rangueil, Toulouse
CHU Bordeaux - Hopital Haut-Lévèque, Bordeaux
CHU Rennes, Rennes
CHRU Tours, Tours
CHU Angers, Angers
GHICL Lille, Lille
Centre Oscar Lambret, Lille
CHRU Lille, Lille
Hôpital Haute Pierre, Strasbourg
Hôpital Edouard HERRIOT, Institut du Cancer - Hospices Civils de Lyon, Lyon
APHP - Hopital Cochin, Paris
APHP - Saint Antoine, Paris
CHU Amiens, Amiens
CHU Poitiers, Poitiers
APHP Beaujon, Clichy
Institut Gustave Roussy, Villejuif
CHU Dijon, Dijon
Institut Paoli-Calmettes, Marseille
CHU Reims, Reims
Hospices Civils de Lyon
OTHER